Lesion-Specific Metabolic Alterations in Relapsing-Remitting Multiple Sclerosis Via 7 T Magnetic Resonance Spectroscopic Imaging.
Journal
Investigative radiology
ISSN: 1536-0210
Titre abrégé: Invest Radiol
Pays: United States
ID NLM: 0045377
Informations de publication
Date de publication:
01 02 2023
01 02 2023
Historique:
pubmed:
13
9
2022
medline:
11
1
2023
entrez:
12
9
2022
Statut:
ppublish
Résumé
Magnetic resonance spectroscopic imaging (MRSI) of the brain enables in vivo assessment of metabolic alterations in multiple sclerosis (MS). This provides complementary insights into lesion pathology that cannot be obtained via T1- and T2-weighted conventional magnetic resonance imaging (cMRI). The aims of this study were to assess focal metabolic alterations inside and at the periphery of lesions that are visible or invisible on cMRI, and to correlate their metabolic changes with T1 hypointensity and the distance of lesions to cortical gray matter (GM). A 7 T MRSI was performed on 51 patients with relapsing-remitting MS (30 female/21 male; mean age, 35.4 ± 9.9 years). Mean metabolic ratios were calculated for segmented regions of interest (ROIs) of normal-appearing white matter, white matter lesions, and focal regions of increased mIns/tNAA invisible on cMRI. A subgroup analysis was performed after subdividing based on T1 relaxation and distance to cortical GM. Metabolite ratios were correlated with T1 and compared between different layers around cMRI-visible lesions. Focal regions of, on average, 2.8-fold higher mIns/tNAA than surrounding normal-appearing white matter and with an appearance similar to that of MS lesions were found, which were not visible on cMRI (ie, ~4% of metabolic hotspots). T1 relaxation was positively correlated with mIns/tNAA ( P ≤ 0.01), and negatively with tNAA/tCr ( P ≤ 0.01) and tCho/tCr ( P ≤ 0.01). mIns/tCr was increased outside lesions, whereas tNAA/tCr distributions resembled macroscopic tissue damage inside the lesions. mIns/tCr was -21% lower for lesions closer to cortical GM ( P ≤ 0.05). 7 T MRSI allows in vivo visualization of focal MS pathology not visible on cMRI and the assessment of metabolite levels in the lesion center, in the active lesion periphery and in cortical lesions. This demonstrated the potential of MRSI to image mIns as an early biomarker in lesion development.
Sections du résumé
BACKGROUND
Magnetic resonance spectroscopic imaging (MRSI) of the brain enables in vivo assessment of metabolic alterations in multiple sclerosis (MS). This provides complementary insights into lesion pathology that cannot be obtained via T1- and T2-weighted conventional magnetic resonance imaging (cMRI).
PURPOSE
The aims of this study were to assess focal metabolic alterations inside and at the periphery of lesions that are visible or invisible on cMRI, and to correlate their metabolic changes with T1 hypointensity and the distance of lesions to cortical gray matter (GM).
METHODS
A 7 T MRSI was performed on 51 patients with relapsing-remitting MS (30 female/21 male; mean age, 35.4 ± 9.9 years). Mean metabolic ratios were calculated for segmented regions of interest (ROIs) of normal-appearing white matter, white matter lesions, and focal regions of increased mIns/tNAA invisible on cMRI. A subgroup analysis was performed after subdividing based on T1 relaxation and distance to cortical GM. Metabolite ratios were correlated with T1 and compared between different layers around cMRI-visible lesions.
RESULTS
Focal regions of, on average, 2.8-fold higher mIns/tNAA than surrounding normal-appearing white matter and with an appearance similar to that of MS lesions were found, which were not visible on cMRI (ie, ~4% of metabolic hotspots). T1 relaxation was positively correlated with mIns/tNAA ( P ≤ 0.01), and negatively with tNAA/tCr ( P ≤ 0.01) and tCho/tCr ( P ≤ 0.01). mIns/tCr was increased outside lesions, whereas tNAA/tCr distributions resembled macroscopic tissue damage inside the lesions. mIns/tCr was -21% lower for lesions closer to cortical GM ( P ≤ 0.05).
CONCLUSIONS
7 T MRSI allows in vivo visualization of focal MS pathology not visible on cMRI and the assessment of metabolite levels in the lesion center, in the active lesion periphery and in cortical lesions. This demonstrated the potential of MRSI to image mIns as an early biomarker in lesion development.
Identifiants
pubmed: 36094811
doi: 10.1097/RLI.0000000000000913
pii: 00004424-202302000-00006
pmc: PMC9835681
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156-165Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 718
Pays : Austria
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: The authors have no conflicts of interest to declare. This study was funded by the Austrian Science Fund (FWF; KLI 718, P 30701, P 34198).
Références
Bitsch A, Kuhlmann T, Stadelmann C, et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann Neurol . 2001;49:793–796.
Li BSY, Regal J, Soher BJ, et al. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol . 2003;24:68–74.
Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain . 2003;126:1782–1789.
Brex P, Parker G, Leary S, et al. Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry . 2000;68:627–632.
Barkhof F, Koeller KK. Demyelinating diseases of the CNS (brain and spine). In: Hodler J, Kubik-Huch RA, Schulthess GK, eds. Diseases of the Brain, Head and Neck, Spine 2020–2023: Diagnostic Imaging. IDKD Springer Series Springer; 2020. Available at: http://www.ncbi.nlm.nih.gov/books/NBK554329/ . Accessed July 9, 2021.
Filippi M, Iannucci G, Cercignani M, et al. A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. Arch Neurol . 2000;57:1017–1021.
Moll NM, Rietsch AM, Thomas S, et al. Multiple sclerosis normal-appearing white matter: pathology-imaging correlations. Ann Neurol . 2011;70:764–773.
Vos CMP, Geurts JJG, Montagne L, et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol Dis . 2005;20:953–960.
Seewann A, Vrenken H, van der Valk P, et al. Diffusely abnormal white matter in chronic multiple sclerosis: imaging and histopathologic analysis. Arch Neurol . 2009;66:601–609.
Vrenken H, Seewann A, Knol DL, et al. Diffusely abnormal white matter in progressive multiple sclerosis: in vivo quantitative MR imaging characterization and comparison between disease types. AJNR Am J Neuroradiol . 2010;31:541–548.
Schmierer K, Wheeler-Kingshott CAM, Boulby PA, et al. Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage . 2007;35:467–477.
Ciccarelli O, Werring DJ, Wheeler-Kingshott CA, et al. Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology . 2001;56:926–933.
Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol . 2004;56:407–415.
Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci . 1979;41:81–91.
Bjartmar C, Kinkel RP, Kidd G, et al. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology . 2001;57:1248–1252.
Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain . 2005;128:2705–2712.
Evangelou N, Esiri M, Smith SM, et al. Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol . 2000;47:391–395.
Filippi M, Rocca MA, Barkhof F, et al. Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol . 2012;11:349–360.
Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology . 2011;259:659–681.
Ineichen BV, Beck ES, Piccirelli M, et al. New prospects for ultra-high-field magnetic resonance imaging in multiple sclerosis. Invest Radiol . 2021;56:773–784.
De Stefano N, Narayanan S, Francis SJ, et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. Arch Neurol . 2002;59:1565–1571.
Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain J Neurol . 2003;126(pt 2):433–437.
Kirov II, Patil V, Babb JS, et al. MR spectroscopy indicates diffuse multiple sclerosis activity during remission. J Neurol Neurosurg Psychiatry . 2009;80:1330–1336.
Bogner W, Gruber S, Trattnig S, et al. High-resolution mapping of human brain metabolites by free induction decay (1)H MRSI at 7 T. NMR Biomed . 2012;25:873–882.
Hangel G, Strasser B, Považan M, et al. Ultra-high resolution brain metabolite mapping at 7 T by short-TR Hadamard-encoded FID-MRSI. Neuroimage . 2018;168:199–210.
Gruber S, Heckova E, Strasser B, et al. Mapping an extended neurochemical profile at 3 and 7 T using accelerated high-resolution proton magnetic resonance spectroscopic imaging. Invest Radiol . 2017;52:631–639.
Heckova E, Strasser B, Hangel GJ, et al. 7 T magnetic resonance spectroscopic imaging in multiple sclerosis: how does spatial resolution affect the detectability of metabolic changes in brain lesions? Invest Radiol . 2019;54:247–254.
Heckova E, Dal-Bianco A, Strasser B, et al. Extensive brain pathologic alterations detected with 7.0-T MR spectroscopic imaging associated with disability in multiple sclerosis. Radiology . 2022;303:141–150.
Hametner S, Dal Bianco A, Trattnig S, et al. Iron related changes in MS lesions and their validity to characterize MS lesion types and dynamics with ultra-high field magnetic resonance imaging. Brain Pathol . 2018;28:743–749.
Dal-Bianco A, Grabner G, Kronnerwetter C, et al. Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging. Acta Neuropathol . 2017;133:25–42.
Absinta M, Dal-Bianco A. Slowly expanding lesions are a marker of progressive MS—yes. Mult Scler J . 2021;27:1679–1681.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol . 2011;69:292–302.
Marques JP, Kober T, Krueger G, et al. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T1-mapping at high field. Neuroimage . 2010;49:1271–1281.
Strasser B, Považan M, Hangel G, et al. (2 + 1)D-CAIPIRINHA accelerated MR spectroscopic imaging of the brain at 7T. Magn Reson Med . 2017;78:429–440.
Kreis R, Boer V, Choi IY, et al. Terminology and concepts for the characterization of in vivo MR spectroscopy methods and MR spectra: background and experts' consensus recommendations. NMR Biomed . 2021;34:e4347.
Strasser B, Chmelik M, Robinson SD, et al. Coil combination of multichannel MRSI data at 7 T: MUSICAL. NMR Biomed . 2013;26:1796–1805.
Bilgic B, Chatnuntawech I, Fan AP, et al. Fast image reconstruction with L2-regularization. J Magn Reson Imaging . 2014;40:181–191.
Naressi A, Couturier C, Devos JM, et al. Java-based graphical user interface for the MRUI quantitation package. MAGMA . 2001;12:141–152.
Považan M, Hangel G, Strasser B, et al. Mapping of brain macromolecules and their use for spectral processing of (1)H-MRSI data with an ultra-short acquisition delay at 7 T. Neuroimage . 2015;121:126–135.
Lin A, Andronesi O, Bogner W, et al. Minimum reporting standards for in vivo magnetic resonance spectroscopy (MRSinMRS): experts' consensus recommendations. NMR Biomed . 2021;34:e4484.
Hangel G, Cadrien C, Lazen P, et al. High-resolution metabolic imaging of high-grade gliomas using 7T-CRT-FID-MRSI. Neuroimage Clin . 2020;28:102433.
Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage . 2006;31:1116–1128.
Dieringer MA, Deimling M, Santoro D, et al. Rapid parametric mapping of the longitudinal relaxation time T1 using two-dimensional variable flip angle magnetic resonance imaging at 1.5 Tesla, 3 Tesla, and 7 Tesla. PLoS One . 2014;9:e91318.
Futatsuya K, Kakeda S, Yoneda T, et al. Juxtacortical lesions in multiple sclerosis: assessment of gray matter involvement using phase difference-enhanced imaging (PADRE). Magn Reson Med Sci . 2016;15:349–354.
Fernando KTM, McLean MA, Chard DT, et al. Elevated white matter myo -inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain . 2004;127:1361–1369.
Llufriu S, Kornak J, Ratiney H, et al. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol . 2014;71:840–847.
Fleischer V, Kolb R, Groppa S, et al. Metabolic patterns in chronic multiple sclerosis lesions and normal-appearing white matter: intraindividual comparison by using 2D MR spectroscopic imaging. Radiology . 2016;281:536–543.
Kirov II, Liu S, Tal A, et al. Proton MR spectroscopy of lesion evolution in multiple sclerosis: steady-state metabolism and its relationship to conventional imaging. Hum Brain Mapp . 2017;38:4047–4063.
Calabrese M, Filippi M, Gallo P. Cortical lesions in multiple sclerosis. Nat Rev Neurol . 2010;6:438–444.
Vercellino M, Masera S, Lorenzatti M, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol . 2009;68:489–502.
Hulst HE, Geurts JJG. Gray matter imaging in multiple sclerosis: what have we learned? BMC Neurol . 2011;11:153.
Bø L, Vedeler CA, Nyland H, et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler J . 2003;9:323–331.
van Horssen J, Brink BP, de Vries HE, et al. The blood-brain barrier in cortical multiple sclerosis lesions. J Neuropathol Exp Neurol . 2007;66:321–328.
Brink BP, Veerhuis R, Breij ECW, et al. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. J Neuropathol Exp Neurol . 2005;64:147–155.
Brief EE, Vavasour IM, Laule C, et al. Proton MRS of large multiple sclerosis lesions reveals subtle changes in metabolite T(1) and area. NMR Biomed . 2010;23:1033–1037.
Kapeller P, McLean MA, Griffin CM, et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol . 2001;248:131–138.
Donadieu M, Le Fur Y, Maarouf A, et al. Metabolic counterparts of sodium accumulation in multiple sclerosis: a whole brain 23 Na-MRI and fast 1 H-MRSI study. Mult Scler J . 2019;25:39–47.
Hingerl L, Strasser B, Moser P, et al. Clinical high-resolution 3D-MR spectroscopic imaging of the human brain at 7 T. Invest Radiol . 2020;55:239–248.
Haast RAM, Ivanov D, Uludağ K. The impact of B1+ correction on MP2RAGE cortical T 1 and apparent cortical thickness at 7T. Hum Brain Mapp . 2018;39:2412–2425.
Liu J, Beck ES, Filippini S, et al. Navigator-guided motion and B0 correction of T2*-weighted magnetic resonance imaging improves multiple sclerosis cortical lesion detection. Invest Radiol . 2021;56:409–416.
Massire A, Seiler C, Troalen T, et al. T1-based synthetic magnetic resonance contrasts improve multiple sclerosis and focal epilepsy imaging at 7 T. Invest Radiol . 2021;56:127–133.